Algernon Retains Renmark Financial Communications
12 mars 2019 23h46 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 12, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Breathtec Announces Name Change to Algernon Pharmaceuticals
14 févr. 2019 07h00 HE
|
Breathtec Biomedical Inc.
New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's...
Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK
31 janv. 2019 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the “Company” or “Nash...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
13 nov. 2018 07h00 HE
|
Breathtec Biomedical Inc.; Nash Pharmaceuticals Inc.
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)...
Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year
13 sept. 2018 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash...
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
02 août 2018 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...